Form 4: Relay Therapeutics Officer Sells Shares to Cover Tax Obligations

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 298 shares of common stock on March 27, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Summary

• On March 27, 2024, Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 298 shares of common stock.
• The sale was executed at a price of $7.7 per share.
• The transaction was to cover income tax withholding obligations related to the vesting of 992 restricted stock units (RSUs) on March 26, 2024.
• Following the transaction, Rahmer beneficially owns 514,679 shares of Relay Therapeutics, which includes 470,848 shares underlying RSUs.
• The sale was conducted in accordance with Relay Therapeutics' policies regarding the vesting of RSUs, and Rahmer had no discretion over the sale.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a routine stock sale to cover tax obligations. It doesn't indicate any significant positive or negative sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This particular transaction appears to be routine, covering tax obligations related to RSU vesting.

Stakeholder Impact

• The sale of shares by an officer could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates